

Eli Lilly partners with Stipple Bio in a $5.9B licensing deal to develop targeted cancer treatments using its Pointillist Platform.
You can purchase shares of Eli Lilly (NYSE:LLY) through any online brokerage.
Other companies in Eli Lilly’s space includes: Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS), AstraZeneca PLC (NYSE:AZN) and Novo Nordisk AS (NYSE:NVO).
Eli Lilly has a consensus price target of $1382.11.
The stock price for Eli Lilly (NYSE: LLY) is $1371.23 last updated November 19, 2026 at 6:16 AM EST.
There are no upcoming dividends for Eli Lilly.
Eli Lilly does not have any upcoming earnings scheduled.
There is no upcoming split for Eli Lilly.
Eli Lilly is in the Health Care sector and Pharmaceuticals industry. They are listed on the NYSE.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for...